What Estelle-35 Treats: Main Uses and Benefits

Estelle-35 is commonly used to help manage symptoms related to systemic imbalance, particularly androgen excess, which can lead to pronounced physical manifestations. These manifestations include severe acne (inflammatory or scarring types), hirsutism (excessive hair growth), and seborrhoea (excessive skin oiliness). It is used in clinical settings where assistance with symptoms related to systemic imbalance is appropriate.

The combination is used for the management of moderate to severe acne related to androgen sensitivity and/or hirsutism in women of reproductive age.

The preparation supports the patient during treatment by addressing physical symptoms and assists with managing androgen-dependent conditions while contributing to oral contraception. This combination may be part of symptomatic management for patients who require relief from hyperandrogenism and need simultaneous support for pregnancy prevention. It is commonly used to help with conditions where symptoms related to systemic imbalance, such as cycle fluctuations, may interfere with daily functioning.

Quick Fact: Relief for Androgen-Driven Symptoms
Primary Focus	Severe acne and hirsutism linked to hormone activity.
Dual Role	Supports symptom management while contributing to oral contraception.
General Benefit	Contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Regulatory References

1. European Medicines Agency therapeutic overview

The use of Estelle-35 is strictly defined by regulatory eligibility criteria, primarily restricting use to women of reproductive age who have reached menarche. The medicine is contraindicated for women who seek contraception alone and must not be used with any other hormonal contraceptive.

Contraindicated Populations (Must Not Use)

The medicine is absolutely prohibited for individuals with a current or history of venous or arterial thromboembolic events (e.g., Deep Vein Thrombosis, Pulmonary Embolism, Stroke, or Myocardial Infarction). Contraindications also include severe hepatic disease where liver function has not returned to normal, liver tumors, known or suspected sex-steroid-influenced malignancies, or a history of meningioma. Patients with severe diabetes mellitus with vascular changes or migraine with focal neurological symptoms are also ineligible.

Age and Reproductive Status

Use is contraindicated during known or suspected pregnancy and is not recommended while breastfeeding. The medicine is not for use in children (pre-menarcheal females) or post-menopausal women (older adults). Women over 35 years of age who smoke are strongly advised against use due to elevated risk of serious cardiovascular events.

Interactions with other medicines and products

Regulatory documents establish specific restrictions and pharmacokinetic interaction patterns for Estelle-35 (Cyproterone acetate/Ethinylestradiol).

Contraindicated Combinations

The medicine is contraindicated for co-administration with other hormonal contraceptives, as this would lead to excessive hormonal exposure. Co-use is also contraindicated with certain combination drug regimens for Hepatitis C (e.g., Ombitasvir/Paritaprevir/Ritonavir pm Dasabuvir) due to the documented risk of liver enzyme elevations (ALT)

.

Metabolic and Exposure-Altering Interactions

Co-administration with hepatic enzyme inducers (e.g., specific anticonvulsants like Phenytoin or Carbamazepine, and the herbal product St. John’s Wort) may decrease the therapeutic effectiveness and increase breakthrough bleeding by accelerating the medicine's metabolic clearance. Conversely, Estelle-35 can inhibit the clearance of other co-administered drugs, potentially increasing their plasma concentrations (e.g., certain corticosteroids, beta-blockers, and benzodiazepines).

Population-Specific Constraint

The medicine is formally contraindicated in patients with severe hepatic disease until liver function has normalized, reflecting a restriction related to the altered drug clearance and accumulation risk.

Estelle-35 is a combination hormonal product containing cyproterone acetate (CPA), a progestin with antiandrogenic activity, and ethinylestradiol (EE), an estrogen. The pharmacodynamic effects are mediated through multiple molecular targets.

CPA acts as an antagonist at the androgen receptor (AR) in target tissues, including skin and hair follicles, preventing the binding and activity of endogenous androgens such as testosterone and dihydrotestosterone (DHT). CPA also functions as an agonist at the progesterone receptor (PR), contributing to the compound's progestogenic properties.

Both CPA and EE exert a negative feedback mechanism on the hypothalamic-pituitary-ovarian (HPO) axis.

• EE acts as an agonist at the estrogen receptor (ER), leading to the suppression of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) release, which inhibits ovulation. Concurrently, EE increases the hepatic synthesis of sex hormone-binding globulin (SHBG), which binds circulating androgens, decreasing the fraction of free, biologically active androgen.
• CPA, via its progestogenic and antigonadotropic actions, further suppresses LH and, consequently, reduces the production of androgens by the ovaries.

Collectively, the systemic physiological consequences include suppression of the ovarian cycle and a reduction in circulating free androgen levels, thereby modulating androgen-dependent processes in peripheral tissues.

Administration Guidelines

Estelle-35 is a fixed-dose preparation delivered exclusively via the oral route as a film-coated tablet, containing 2.0 mg Cyproterone acetate and 0.035 mg Ethinylestradiol. Its use follows a cyclic regimen.

---

Administration Principle	Protocol
Dosing Schedule	One active tablet daily for 21 consecutive days. Subsequent packs are started after a 7-day tablet-free interval (or 7 inactive tablets).
Timing & Consistency	The tablet must be taken at about the same time every day and in the order directed on the blister pack. The tablet is typically taken with some liquid and may be taken after food.
Special Restriction	The medicine must not be used concurrently with any other hormonal contraceptive (e.g., pill, patch, or ring).
Duration Principle	Treatment should generally be discontinued 3 to 4 cycles after the androgen-related condition has completely resolved. Continuation solely for contraception is not recommended.

---

Procedural Rules for Use

• Missed Dose Rule: Contraceptive protection may be reduced if an active tablet is delayed by more than 12 hours from the usual time. If missed by less, take it immediately and continue the schedule as normal.
• Interruption Constraint: Active tablet intake must never be discontinued for longer than 7 days to ensure the necessary hormonal suppression.
• Starting Use: The first active tablet should be taken on Day 1 of the natural menstrual cycle. Specific starting rules apply when switching from other hormonal methods or following delivery.

Research Evidence / Overview of Studies for Estelle-35

This summary explains the types of research that have been conducted for Estelle-35's approved uses. The aim is to describe what has been observed in study settings. Findings describe group patterns, not personal outcomes. Research does not determine whether an individual will respond similarly.

Evidence for use in Severe Acne

Research examined Estelle-35 in studies involving women with severe acne where other treatments were unsuccessful. Studies monitored outcomes related to inflammatory or irritative states, such as measurements of acne lesion counts and the overall assessment of skin condition by a clinician.

Findings describe patterns observed in the studies where measurements of total acne lesion counts evolved in the observed populations during the study period. Research describes measurements recorded in severity scores and outcomes linked to inflammatory or irritative states (seborrhoea). The evidence contributes to understanding symptom patterns primarily over short-term to intermediate follow-up durations.

Evidence for use in Mild to Moderate Hirsutism

Estelle-35 was evaluated in studies of women experiencing mild to moderate hirsutism, a condition marked by functional limitations. Studies monitored outcomes related to systemic or functional imbalance, primarily by monitoring the Ferriman-Gallwey score, which is a standardized measurement of excessive hair growth. Studies report how symptoms evolved in the observed populations over the extended observation periods.

What is Still Uncertain About Estelle-35 Research

Despite the existing research, certainty remains low in some areas, and research is ongoing. Evidence quality varies across studies, and many follow-up durations were limited, meaning we know less about outcomes over multiple years. Data for certain patient groups, such as those with significant liver or kidney impairment, remain insufficient. What remains uncertain includes the lack of long-term evidence beyond the initial trial periods and where comparative evidence is lacking.

Common questions about Estelle-35 (FAQ)

Q: Is Estelle-35 a high-dose hormonal medication?

According to official product information and classification systems, this medicine is described as a low-dose hormonal preparation. This classification refers to the ethinylestradiol component, which contains 35 mu g. Low-dose formulations contain less estrogen compared to historical oral contraceptives.

Q: How quickly does Estelle-35 start working for its main purpose?

Studies and official information indicate that for the treatment of androgen-dependent conditions like acne and hirsutism, patients typically observe clinical improvement over several menstrual cycles. The treatment duration is generally described as continuing for three to four cycles after the condition has completely resolved.

Q: How does Estelle-35 compare to other medications with the same active ingredients?

Medicines containing the identical combination of active ingredients (Cyproterone acetate 2 mg / Ethinylestradiol 35 mu g) are marketed under various brand names internationally. This combination is known generically as Co-cyprindiol.

Q: Do many people take Estelle-35 for PCOS symptoms?

Some authoritative product information includes the treatment of symptoms associated with Polycystic Ovary Syndrome (PCOS) as an approved indication for this medicine. The medicine is described as working by managing conditions that result from excessive androgen (male hormone) activity.

Q: Are there generic versions of Estelle-35 available?

Yes, regulatory documents acknowledge that medicines containing the same two active ingredients are available globally under different brand names. These are often referred to by the generic designation, Co-cyprindiol.

Q: Do side effects usually go away after the first few months on Estelle-35?

Official information notes that certain common effects, particularly intermenstrual bleeding or spotting, may occur during the first few cycles (e.g., one to two months). These effects may resolve as the body adjusts to the hormonal medication during the initial period.

Q: Does alcohol interact with Estelle-35?

The use of alcohol is generally described in regulatory context as having a minor interaction with the ethinylestradiol component of the medicine. Regulatory sources generally recommend consulting a healthcare provider regarding alcohol consumption while taking the medicine.

Q: Can taking Estelle-35 affect how my liver works?

Because this medicine is processed by the liver, regulatory documents contain warnings about the potential for changes in liver function. It is therefore strictly contraindicated for use in patients with existing severe hepatic disease or certain liver tumors.

Q: Do antibiotics reduce the effectiveness of Estelle-35?

The effectiveness of the medicine may be reduced by specific types of antibiotics that are known as hepatic enzyme inducers (such as rifampicin). However, many common, non-enzyme-inducing antibiotics do not appear to cause this specific interaction.

Q: Are there any herbal supplements that interact with Estelle-35?

The herbal product St. John’s Wort (Hypericum perforatum) is specifically identified in official information as an enzyme-inducing agent. Taking this supplement is advised against in regulatory information because it can potentially reduce the effectiveness of this medicine.

Q: Can Estelle-35 be used by women over 40?

Regulatory documents indicate that the risk of serious side effects, such as blood clots, increases significantly with age, particularly in women over 35 years old. Use in this age group is a consideration that involves the careful assessment of individual risk factors, as described in regulatory warnings.

Q: Is there an age limit for starting Estelle-35?

This medicine is only indicated for use in women of reproductive age who have already reached menarche (started their periods). It is not intended for use in pre-menarcheal females or women who are post-menopausal.

Q: What types of cancers are mentioned in the safety information for Estelle-35?

The medicine is strictly contraindicated in patients with certain liver tumors (benign or malignant) or a history of sex-steroid-influenced malignancies (cancers sensitive to hormones). These include some types of breast and genital cancers.

Q: Is Estelle-35 considered a first-line treatment for hirsutism?

Official therapeutic indications state that for the treatment of severe acne, the medicine is generally reserved for use only when other treatments, such as oral antibiotics or topical treatments, have not been successful. This description is consistent with its positioning for managing specific symptoms.

Q: Can Estelle-35 cause changes to vision?

Some regulatory documents list changes in vision, such as difficulty tolerating contact lenses, as a common effect. However, sudden or severe vision changes are noted as a potential symptom of a serious, but rare, cardiovascular event.

Q: Is there a link between Estelle-35 and high blood pressure?

Hormonal medicines of this type have been associated with potential increases in blood pressure. Official warnings suggest blood pressure monitoring is a consideration while taking the medication, and it is strictly contraindicated in women with uncontrolled high blood pressure.

Q: How long does the medication stay in your system after stopping Estelle-35?

Pharmacokinetic studies—which describe how the body handles the medicine—indicate that the cyproterone acetate component has a terminal elimination half-life of approximately 1.7 days. This is the time it takes for half of the substance to be eliminated from the body.

Q: Will I get my period during the inactive pill week of Estelle-35?

During the 7-day tablet-free interval, a withdrawal bleeding is expected to occur, which is sometimes referred to as a period. Official product information states this bleeding usually starts two to three days after taking the last active tablet.

Q: Can certain foods impact the absorption of Estelle-35?

Regulatory context notes that consuming grapefruit or grapefruit juice may potentially increase the plasma concentrations of the ethinylestradiol component. General administration conditions include taking the tablet with some liquid, often with or after food.

Q: Does Estelle-35 change cholesterol levels?

Clinical studies have observed changes in lipid and lipoprotein levels, such as cholesterol and triglycerides, which is a common effect observed with hormonal medicines of this type. These changes are part of the drug’s metabolic profile.

Q: Are there specific types of surgery that require stopping Estelle-35 beforehand?

Due to the risk of blood clots (venous thromboembolism), regulatory information advises that the medicine may need to be temporarily stopped before certain types of surgery. This precaution is especially relevant for procedures that involve prolonged periods of immobilization.

Storage and Disposal of Estelle-35

Required Storage Conditions

Estelle-35 must be stored in a cool, dry place where the temperature stays below 30 C.

Storage Requirement	Rule
Temperature	Store below 30 C.
Protection	Must be protected from light and moisture.
Container	Keep in the original blister pack until use, as tablets removed from the pack may not keep well.
Child Safety	Must be kept out of the sight and reach of children.

Disposal Instructions

Unused, expired, or damaged Estelle-35 must not be disposed of via household waste or wastewater. For proper disposal, any leftover medicine must be returned to the pharmacist.